Quick Answer
MUSTANG BIO, INC. reported Cash and Equivalents of $17.27 million for fiscal year 2025.
MUSTANG BIO, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $17.27M | +152.5% |
| 2024 | $6.84M | +9.7% |
| 2023 | $6.23M | -91.8% |
| 2022 | $75.66M | -31.0% |
| 2021 | $109.62M | +12.1% |
| 2020 | $97.80M | +59.3% |
| 2019 | $61.41M | +272.9% |
| 2018 | $16.47M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.98M | +438.6% | +50.0% |
| June 30, 2025 | $12.66M | +196.6% | -11.1% |
| March 31, 2025 | $14.23M | +964.4% | +108.1% |
| December 31, 2024 | $6.84M | +9.7% | +94.0% |
| September 30, 2024 | $3.52M | -63.1% | -17.4% |
| June 30, 2024 | $4.27M | -72.3% | +219.2% |
| March 31, 2024 | $1.34M | -97.7% | -78.6% |
| December 31, 2023 | $6.23M | -91.8% | -34.8% |
- MUSTANG BIO, INC. showed an increase of +152.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, MUSTANG BIO, INC.’s cash and equivalents has grown by 4.8% (from $16.47 million to $17.27 million).
- The most recent figure is from MUSTANG BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: